ArticleEuropean journal of nuclear medicine and molecular imaging2026
Head-to-head comparison of
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-flutemetamol (FMM) have demonstrated diagnostic utility for CA. However, to our knowledge, no direct head-to-head comparison has been performed in cardiac imaging. This study compared the myocardial uptake patterns of PiB and FMM PET in patients with biopsy-confirmed wild-type transthyretin-CA (ATTRwt-CA).
methodsSixteen patients with ATTRwt-CA underwent PiB and FMM PET/CT. PET was performed dynamically for 25 min after tracer injection. Retention index (RI) images were derived from dynamic data, and standardized uptake value (SUV) images were calculated from static images acquired 10–20 min post-injection. Global myocardial uptake was assessed using myocardial-to-blood pool ratios (MBR-RI and MBR-SUV). Segmental uptake was evaluated using relative segmental uptake (RSU) and segmental MBR on 17-segment polar maps for 13 patients.
resultsMedian RI-MBR values were 1.35 [1.28–1.63] for PiB and 1.50 [1.13–1.95] for FMM, showing a significant correlation (ρ = 0.580) without a significant difference. Median SUV-MBR values were 1.92 [1.64–2.20] for PiB and 1.87 [1.26–2.19] for FMM, with a strong correlation (ρ = .859) and no significant difference. Pooled segmental analysis demonstrated significant correlations for RSU (ρ = 0.635) and segmental MBR (ρ = 0.683). Concordance was preserved in both the treated and untreated subgroups.
conclusionPiB and FMM PET provide highly concordant semi-quantitative assessments of myocardial amyloid burden in ATTRwt-CA. This first head-to-head cardiac comparison supports the need for harmonization strategies for cardiac amyloid PET in multicenter studies and longitudinal therapeutic monitoring.
Indexed as
Identifiers
41882333What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.